The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

NeuroSense Secures Brazilian Patent for PrimeC Composition Through 2042

Key Facts

1Brazil granted NeuroSense a patent for the PrimeC composition, providing protection through October 2042.

2This grant follows previous patent approvals in the United States and Australia.

NeuroSense Therapeutics Ltd. has officially been granted a patent in Brazil for its lead drug candidate, PrimeC, marking a significant expansion of its intellectual property. This patent provides the company with exclusive protection in the Brazilian market until October 2042, safeguarding its therapeutic composition. The approval follows similar patent grants previously secured by the firm in the United States and Australia, strengthening its global footprint. By securing this patent, NeuroSense effectively protects its research investments and ensures long-term exclusivity for its flagship product. This development is expected to bolster the company's valuation and secure future revenue streams within the competitive biotech sector. The move underscores NeuroSense's strategic focus on building a robust global intellectual property portfolio for its innovative treatments.